Role of interleukin-6 in a non-septic shock model induced by zymosan

European Cytokine Network

Volumn 10, Issue 2, 1999, Pages 191-203

  Cuzzocrea, Salvatore ^a   De Sarro, Giovambattista ^b   Costantino, Giuseppina ^b   Mazzon, Emanuela ^b   Laurà, Rosaria ^b   Ciriaco, Emilia ^b   De Sarro, Angela ^b   Caputi, Achille P ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE

Author keywords

Free radicals; Knock out IL 6; Nitric oxide; Shock; Zymosan

Indexed keywords

3 NITROTYROSINE; CYTOKINE ANTIBODY; DNA; INTERLEUKIN 6; INTESTINE ENZYME; LIVER ENZYME; LUNG ENZYME; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRATE; NITRITE; PEROXYNITRITE; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE INJURY; KNOCKOUT MOUSE; LIPID PEROXIDATION; LUNG INJURY; MACROPHAGE; MITOCHONDRIAL RESPIRATION; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PERITONEUM EXUDATE; PERITONITIS; SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; ASCITES; ASCITIC FLUID; DNA DAMAGE; ENERGY METABOLISM; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; INTESTINE, SMALL; LEUKOCYTE COUNT; LIPID PEROXIDATION; LIVER; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE ORGAN FAILURE; NAD; NEUTROPHILS; NITRATES; NITRITES; OXIDATIVE PHOSPHORYLATION; PERITONITIS; PEROXIDASE; SHOCK; TYROSINE; ZYMOSAN;

ANIMALIA;

EID: 0032782850     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. 1. Deitch E A, Ma W J, Ma L, Berg R D, Specian R D. 1990. Protein malnutrition predisposes to inflammatory-induced gut-origin septic states. Ann. Surg. 221: 560.
2. 2. Demling R, Nayak U, Ikegami K, LaLonde C. 1994. Comparison between lung and liver peroxidation and mortality after zymosan peritonitis in the rats. Shock. 2: 222.
3. 3. Goris R J, van Bebber I P, Mollen R M, Koopman J P. 1991. Dose selective decontamination of the gastrointestinal tract prevent multiple organ failure? An experimental study. Arch. Surg. 126: 561.
4. 4. Cuzzocrea S, Filippelli A, Zingarelli B, Falciani M, Caputi A P, Russi F. 1997. Role of nitric oxide in a non septic shock model induced by zymosan in the rat. Shock. 7: 351.
5. 5. Cuzzocrea S, Zingarelli B, Sautebin L, Rizzo A, Crisafulli C, Campo G M, Costantino G, Calapai G, Nava F, Di Rosa M, Caputi A P. 1997. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. Shock. 8: 268.
6. 6. Mainous M R, Ertel W, Chaudry I H, Deitch E A. 1993. The gut: a cytokine-generating organ in systemic inflammation? Shock. 4: 193.
7. 7. Von Asmuth E J, Maessen J G, van der Linden C J, Buurman W A. 1990. Tumor necrosis factor alpha (TNF-α) and interleukin-6 in A zymosan-induced shock model. Scand J. Immunol. 32: 319.
8. 8. Jansen M J, Hendriks T, Vogels M T, van der Meer J W, Goris R J. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit. Care Med. 24: 1196.
9. 9. Damas J, Remacle-Volon G, Bourdon V. 1993. Platelet-activating factor and vascular effects of zymosan in rats. Eur. J. Pharmacol. 231: 231.
10. 10. Cuzzocrea S, Zingarelli B, Caputi AP. 1998. Peroxynitrite-mediated DNA strand breakage activates poly (ADP-ribose) synthetase and causes cellular energy depletion in a nonseptic shock model induced by zymosan in the rat. Shock. 9: 336.
11. 11. Cuzzocrea S, Zingarelli B, Costantino G, Sottile A, Teti D, Caputi A P. 1998. Protective effect of poly (ADP-Ribose) synthetase inhibition on multiple organ failure following zymosan-induced peritonitis. Crit. Care Med. (in press).
12. 12. Kishimoto T. 1989. The biology of interleukin-6. (Review) Blood 74: 1.
13. 13. Baumann H, Jahreis G P, Sauder D N, Koj A. 1984. Human keratinocytes and monocytes release factors which regulate the synthesis of major acute phase plasma proteins in hepatic cells from man, rat, and mouse. J. Biol. Chem. 262: 9756.
14. 14. Jirik F R, Podor T J, Hirano T, Kishimoto T, Loskutoff D J, Carson D A, Lotz M. 1989. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J. Immunol. 142: 144.
15. 15. Houssiau F A, Bukasa K, Sindic C J, van Damme J, van Snick J. 1988. Elevated levels of the 26K human hybridoma growth factor (interleukin-6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin. Exp. Immunol. 71: 320.
16. 16. Waage A, Brandtzaeg P, Halstensen A, Kierrulf P, Espevik T. 1989. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-6, interleukin-1, and fatal outcome. J. Exp. Med. 169: 333.
17. 17. Hirano T. 1992. Interleukin-6 and its relation to inflammation and disease. (Review) Clin. Immunol. Immunopath. 62: S60.
18. 18. Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL, Caputi AP, Szabò C. 1997. Role of peroxynitrite and activation of Poly (ADP Ribose) synthetase in the vascular failure induced by zymosan-activated plasma. Br. J. Pharmacol. 122: 493.
19. 19. Darley-Usmar V, Halliwell B. 1996. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. (Review) Pharm. Res. 13: 649.
20. 20. Schraufstatter I U, Hinshaw D B, Hyslop P A, Spragg R G, Cochrane C G. 1986. Oxidant injury of cells: DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J. Clin. Invest. 77: 1312.
21. 21. Mullane K M, Westlin W, Kraemer R. 1988. Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. (Review) Ann. N. Y. Acad. Sci. 524: 103.
22. 22. Alonzi T, Fattori E, Cappelletti M, Ciliberto G, Poli V. 1998. Impaired STAT3 activation following localized inflammatory stimulus in IL-6 deficient mice. Cytokine 10: 13.
23. 23. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315.
24. 24. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, de Benedetti F, Poli V, Ciliberto G. 1998. Interleukin-6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187: 461.
25. 25. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan G A, Costantini F. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13: 1189.
26. 26. Tilg H, Dinarello C A, Mier J W. 1997. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. (Review) Immunol. Today 18: 428.
27. 27. Van de Loo F A, Joosten L A, van Lent P L, Arntz O J, van den Berg W B. 1995. Role of interleukine-1, tumor necrosis factor, and interleukine-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38: 164.
28. 28. Youker K, Smith C W, Anderson D C, Miller D, Michael L H, Rossen R D, Entman M L. 1992. Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. J. Clin. Invest. 89: 602.
29. 29. Kharazmi A, Nielsen H, Rechnitzer C, Bendtzen K. 1989. Interleukin-6 primes human neutrophil and monocyte oxidative burst response. Immunol. Lett. 21: 177.
30. 30. Dreyer W J, Smith C W, Michael L H, Rossen R D, Hughes B J, Entman M L, Anderson D C. 1989. Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium. Circ. Res. 65: 1751.
31. 31. Biffi W L, Moore E E, Moore F A, Barnett C C Jr, Silliman C C, Peterson V M. 1996. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J. Leukoc. Biol. 59: 569.
32. 32. Borish L, Rosenbaum R, Albury L, Clark S. 1989. Activation of neutrophils by recombinant interleukin-6. Cell Immunol. 121: 280.
33. 33. Kukielka G L, Youker K A, Hawkins H K, Perrard J L, Michael L H, Ballantyne C M, Smith C W, Entman M L. 1994. Regulation of ICAM-1 and IL-6 in myocardial ischemia: effect of reperfusion. (Review) Ann. N. Y. Acad. Sci. 723: 258.
34. 34. Cicco N A, Lindemann A, Content J, Vandenbussche P, Lubbert M, Gauss J, Mertelsmann R, Herrmann F. 1990. Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood 75: 2049.
35. 5a responsible for stimulation of IL-6 synthesis. J. Immunol. 148: 3937.
36. 5a leukotaxis in vitro and under stimulated in viva condition. J. Immunol. 120: 109.
37. 5a as the major chemotactic factor. Infect. Immun. 1: 521.
38. 38. Murohara T, Kugiyama K, Sugiyama S, Ohgushi M, Yasue H. 1993. Activated human polymorphonuclear leukocytes elicit endothelium-dependent contraction in isolated pig coronary arteries. J. Cardiovasc. Pharmacol. 21: 760.
39. 39. Mehta J L, Lawson D L, Nicolini F A, Ross M H, Player D W. 1991. Effects of activated polymorphonuclear leukocytes on vascular smooth muscle tone. Am. J. Physiol. 261: H327.
40. 40. Fantone J C, Ward P A. 1982. A review: role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am. J. Pathol. 107: 395.
41. 41. Auger M J. 1989. Mononuclear phagocytes. Br. Med. J. 298: 546.
42. 42. Johnston R B Jr. 1988. Monocytes and macrophages. (Review) N. Engl. J. Med. 318: 747.
43. 43. Nathan C F. 1987. Secretory products of macrophages. (Review) J. Clin. Invest. 79: 319.
44. 44. Calandra T, Gerain J, Heumann D, Baumgartner J D, Glauser M P. 1991. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokines. Am. J. Med. 91: 23.
45. 45. Goris R J. 1990. Mediators of multiple organ failure. (Review) Intensive Care Med. 16S: 192.
46. 46. Perretti M, Solito E, Parente L. 1992. Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. Agents Actions 35: 71.
47. 5a and proteins with the characteristics of IL-8/neutrophil-activating protein-1. J. Immunol. 146: 677.
48. 48. Van Bebber I P, Boekholz K F, Goris R J, Schillings P H, Dinges H P, Bahrami S, Redl S H, Schlag G. 1989. Neutrophil function and lipid peroxidation in rat model of multiple organ failure. J. Surg. Res. 47: 471.
49. 49. Szabó C, Lim L H, Cuzzocrea S, Getting S J, Zingarelli B, Flower R J, Salzman A L, Perretti M. 1997. Inhibition of poly (ADP-ribose) synthetase alternates neutrophil recruitment and exerts anti-inflammatory effects. J. Exp. Med. 186: 1041.
50. 50. Libert C, Van Molle W, Brouckaert P, Fiers W. 1996. Alpha1-antitrypsin inhibits the lethal response to TNF in mice. J. Immunol. 157: 5126.
51. 51. Mancuso G, Tomasello F, Migliardo M, Delfino D, Cochran J, Cook JA, Teti G. 1994. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect. Immun. 62: 4997.
52. 52. Barton B E, Jackson J V. 1993. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 61: 1496.
53. 53. Hirano T, Akira S, Taga T, Kishimoto T. 1990. Biological and clinical aspects of interleukin-6. (Review) Immunol. Today 11: 443.
54. 54. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V. 1994. Defective inflammatory response in interleukin-6-deficient mice. J. Exp. Med. 180: 1243.
55. 55. Fantuzzi G, Dinarello CA. 1996. The inflammatory response in interleukin-1β-deficient mice: comparison with other cytokine-related knock-out mice. (Review) J. Leukoc. Biol. 59: 489.
56. 56. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P, Bistoni F, Poli V. 1996. Impaired neutrophil response and CD4 T helper cell 1 development in interleukin 6-deficent mice infected Candida albicans. J. Exp. Med. 183: 1345.
57. 57. Flesch I E, Kaufmann S H. 1990. Stimulation of antibacterial macrophage activities by B-cell stimulatory factor-2 (interleukin-6). Infect. Immun. 58: 269.
58. 58. Starnes H F Jr, Pearee M K, Tewari A, Yim J H, Zou J C, Abrams J S. 1990. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol. 145: 4185.
59. 59. Denis M. 1992. Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6 or direct administration of IL-6. J. Leukocyte Biol. 52: 197.
60. 60. May L T, Neta R, Moldawer L L, Kenney J S, Patel K, Sehgal P B. 1993. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J. Immunol. 151: 3225-36.
61. 61. Heremans H, Dillen C, Put W, van Damme J, Billiau A. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22: 2395.